Literature DB >> 22171703

An rs9621532 variant near the TIMP3 gene is not associated with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in a Chinese Han population.

Renpan Zeng1, Feng Wen, Xiongze Zhang, Chengguo Zuo, Meng Li, Hui Chen, Kunfang Wu.   

Abstract

BACKGROUND: Recently, two genome-wide association studies with large cohorts both identified rs9621532, a new single nucleotide polymorphism (SNP) that is associated with advanced age-related macular degeneration (AMD) and located near the TIMP3 gene. Previous studies have demonstrated that AMD and polypoidal choroidal vasculopathy (PCV) share some common genetic background and that the incidence of PCV is higher in Asian populations than Caucasian populations. In this study, we aimed to investigate whether the rs9621532 SNP is associated with neovascular AMD (nAMD) and PCV in a Chinese Han population.
METHODS: We performed a case-control study in a Chinese Han population. The rs9621532 SNP was genotyped in 136 patients with nAMD, 195 patients with PCV, and 181 control individuals using the Multiplex SNaPshot system and the direct DNA sequencing technique. Rs9621532 genotypes and allele frequencies in the nAMD, PCV and control groups were evaluated using PLINK software.
RESULTS: In the nAMD, PCV, and control groups, the minor allele frequencies of the rs9621532 variant were 0.05147, 0.02564, and 0.03039, respectively. The rs9621532 SNP was not significantly associated with susceptibility to nAMD (p = 0.1773) or PCV (p = 0.6933). None of the p-values for the additive or dominant models were found to be statistically significant in the nAMD or PCV groups. No recessive homozygotes were genotyped in any of the three groups.
CONCLUSIONS: No evidence was found to support an association between the rs9621532 variant and susceptibility to either nAMD or PCV in a Chinese Han population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22171703     DOI: 10.3109/13816810.2011.643440

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  6 in total

1.  Associations of the intestinal microbiome with the complement system in neovascular age-related macular degeneration.

Authors:  Denise C Zysset-Burri; Irene Keller; Lieselotte E Berger; Carlo R Largiadèr; Matthias Wittwer; Sebastian Wolf; Martin S Zinkernagel
Journal:  NPJ Genom Med       Date:  2020-09-01       Impact factor: 8.617

2.  COL1A2 polymorphic markers confer an increased risk of neovascular age-related macular degeneration in a Han Chinese population.

Authors:  Chengguo Zuo; Feng Wen; Meng Li; Xiongze Zhang; Hui Chen; Kunfang Wu; Renpan Zeng
Journal:  Mol Vis       Date:  2012-06-30       Impact factor: 2.367

Review 3.  Matrix Metalloproteinases in Age-Related Macular Degeneration (AMD).

Authors:  Luis García-Onrubia; Fco Javier Valentín-Bravo; Rosa M Coco-Martin; Rogelio González-Sarmiento; J Carlos Pastor; Ricardo Usategui-Martín; Salvador Pastor-Idoate
Journal:  Int J Mol Sci       Date:  2020-08-18       Impact factor: 5.923

Review 4.  Molecular Genetic Mechanisms in Age-Related Macular Degeneration.

Authors:  Aumer Shughoury; Duriye Damla Sevgi; Thomas A Ciulla
Journal:  Genes (Basel)       Date:  2022-07-12       Impact factor: 4.141

5.  Serum levels of matrix metalloproteinase 2 and matrix metalloproteinase 9 elevated in polypoidal choroidal vasculopathy but not in age-related macular degeneration.

Authors:  Renpan Zeng; Feng Wen; Xiongze Zhang; Yu Su
Journal:  Mol Vis       Date:  2013-03-21       Impact factor: 2.367

Review 6.  Mechanism of inflammation in age-related macular degeneration: an up-to-date on genetic landmarks.

Authors:  Francesco Parmeggiani; Francesco S Sorrentino; Mario R Romano; Ciro Costagliola; Francesco Semeraro; Carlo Incorvaia; Sergio D'Angelo; Paolo Perri; Katia De Nadai; Elia Bonomo Roversi; Paola Franceschelli; Adolfo Sebastiani; Michele Rubini
Journal:  Mediators Inflamm       Date:  2013-11-27       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.